DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR CYMBALTA
» See Plans and Pricing
All Clinical Trials for Cymbalta
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00105989 | Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder | Completed | Boehringer Ingelheim | Phase 3 | 2005-03-01 | The purpose of this study is to assess the efficacy and safety of duloxetine compared with placebo in the prevention of depressive recurrences among patients with recurrent major depressive disorder. |
| NCT00105989 | Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder | Completed | Eli Lilly and Company | Phase 3 | 2005-03-01 | The purpose of this study is to assess the efficacy and safety of duloxetine compared with placebo in the prevention of depressive recurrences among patients with recurrent major depressive disorder. |
| NCT00114127 | Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome | Completed | Massachusetts General Hospital | Phase 3 | 2004-06-01 | The purpose of this study is to examine the safety and efficacy of duloxetine for the treatment of social anxiety disorder. |
| NCT00177671 | Antidepressant Medication Plus Donepezil for Treating Late-life Depression | Completed | National Institute of Mental Health (NIMH) | Phase 4 | 2003-12-01 | This study will determine the effectiveness of combining escitalopram, venlafaxine, or duloxetine with donepezil, a medication used in Alzheimer's disease, in improving memory, concentration, attention, and problem solving abilities, and reducing the risk of depressive relapse in older individuals with depression. |
| NCT00177671 | Antidepressant Medication Plus Donepezil for Treating Late-life Depression | Completed | University of Pittsburgh | Phase 4 | 2003-12-01 | This study will determine the effectiveness of combining escitalopram, venlafaxine, or duloxetine with donepezil, a medication used in Alzheimer's disease, in improving memory, concentration, attention, and problem solving abilities, and reducing the risk of depressive relapse in older individuals with depression. |
| NCT00185575 | Duloxetine for the Treatment of Dysthymia | Completed | Eli Lilly and Company | N/A | 2004-09-01 | The purpose of this study is to test the hypothesis that duloxetine (Cymbalta), in doses of 60 or 120 mg/day, is an effective and tolerable treatment for adult outpatients suffering from dysthymia. Dysthymia is chronic, mild depression characterized by feeling sad or low more days than not for more than 2 years. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Cymbalta
Condition Name
Condition MeSH
Clinical Trial Locations for Cymbalta
Trials by Country
Clinical Trial Progress for Cymbalta
Clinical Trial Phase
Clinical Trial Sponsors for Cymbalta
Sponsor Name
